News
VRDN
16.82
-3.50%
-0.61
Viridian Therapeutics Price Target Cut to $26.00/Share From $27.00 by Evercore ISI Group
Dow Jones · 1d ago
Viridian Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 1d ago
Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26
Benzinga · 1d ago
Evercore ISI Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)
TipRanks · 1d ago
Fairmount Healthcare Fund II buys 1,176,470 Viridian shares for $20 million
PUBT · 3d ago
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
TipRanks · 3d ago
Viridian Therapeutics Raises $359 Million in Offerings
TipRanks · 5d ago
Viridian prices USD 250 million 1.75% convertible notes due 2032
PUBT · 5d ago
Weekly Report: what happened at VRDN last week (0504-0508)?
Weekly Report · 5d ago
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)
TipRanks · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
Reuters · 05/07 17:50
BUZZ-U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
Reuters · 05/07 15:41
BUZZ-Viridian Therapeutics drops on increased stock, convertible bond offerings
Reuters · 05/07 14:39
Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00
TipRanks · 05/07 11:24
Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
TipRanks · 05/07 06:49
Viridian Therapeutics prices upsized $350M concurrent stock, and convertible notes offerings
Seeking Alpha · 05/07 05:36
*Viridian Therapeutics Plans to Use Proceeds to Repay Debt, Fund Studies for Thyroid Eye Disease Franchise, Advance R&D >VRDN
Dow Jones · 05/07 03:17
*Viridian Therapeutics Offerings Expected to Close May 11 >VRDN
Dow Jones · 05/07 03:16
*Viridian Therapeutics Estimates Net Proceeds From Offerings of Around $334.7M >VRDN
Dow Jones · 05/07 03:16
*Viridian Therapeutics Prices $225.0M Upsized Public Offering of 1.75% Convertible Senior Notes Due 2032 >VRDN
Dow Jones · 05/07 03:15
More
Webull provides a variety of real-time VRDN stock news. You can receive the latest news about Viridian Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.